Search results
Showing 31 to 45 of 112 results for paclitaxel
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
Optilume for treating recurrent bulbar urethral strictures (HTG649)
Evidence-based recommendations on Optilume for treating recurrent bulbar urethral strictures.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]
Topic prioritisation
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Evidence-based recommendations on using coronary artery stents in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.
Show all sections
In development Reference number: GID-TA10248 Expected publication date: TBC